NASDAQ: RNA
Atrium Therapeutics, Inc.CIK 0002093101 · SIC 2834 · Pharmaceutical Preparations
Small by assets
Assets $281M
as of Oct 27, 2026
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (WCN 10-Q) is open in full — no account needed.
8-K
Filed Oct 8, 2026
· Period ending Oct 7, 2026
Summary not yet generated.
10-Q
Filed Aug 13, 2026
· Period ending Jun 30, 2026
Summary not yet generated.
Partner
Trade RNA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
8-K
Filed Aug 13, 2026
· Period ending Aug 13, 2026
Summary not yet generated.
8-K
Filed Jul 14, 2026
· Period ending Jul 14, 2026
Summary not yet generated.
10-Q
Filed May 14, 2026
· Period ending Mar 31, 2026
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 13, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Statements of Operations and Comprehensive Loss (Unaudited)
(in thousands except per share data)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | 3,004 | 3,847 | 22,639 | 5,420 |
| Operating expenses: | ||||
| Research and development | 15,343 | 13,293 | 32,000 | 20,230 |
| General and administrative | 10,279 | 3,418 | 30,537 | 5,506 |
| Total operating expenses | 25,622 | 16,711 | 62,537 | 25,736 |
| Loss from operations | (22,618) | (12,864) | (39,898) | (20,316) |
| Other income (expense) | ||||
| Interest income | 2,104 | — | 2,757 | — |
| Other income (expense), net | 328 | (15) | 322 | (12) |
| Total other income (expense) | 2,432 | (15) | 3,079 | (12) |
| Net loss | (20,186) | (12,879) | (36,819) | (20,328) |
| Basic and diluted net loss per common share | (1.18) | (0.75) | (2.15) | (1.19) |
| Weighted average common shares outstanding used in the calculation of basic and diluted net loss per common share | 17,106 | 17,106 | 17,106 | 17,106 |
| Other comprehensive loss: | ||||
| Net unrealized loss on short-term investments | (235) | — | (235) | — |
| Comprehensive loss | (20,421) | (12,879) | (37,054) | (20,328) |
Condensed Balance Sheets (Unaudited)
(in thousands, except par value)
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | 72,334 | — |
| Short-term investments | 191,566 | — |
| Prepaid assets | 4,506 | 1,535 |
| Restricted cash, current portion | 311 | — |
| Other current assets | 6,334 | 1,310 |
| Total current assets | 275,051 | 2,845 |
| Restricted cash, net of current portion | 106 | — |
| Property and equipment, net | 4,066 | 2,724 |
| Right-of-use asset | 1,289 | 2,784 |
| Total assets | 280,512 | 8,353 |
| Liabilities and Stockholders’ Equity / Former Parent’s Deficit | ||
| Current liabilities: | ||
| Accounts payable | 3,513 | 4,398 |
| Accrued liabilities | 13,312 | 8,945 |
| Accrued compensation | 3,962 | 3,147 |
| Lease liabilities | 1,683 | 3,672 |
| Deferred revenue, current portion | 9,038 | 21,639 |
| Total current liabilities | 31,508 | 41,801 |
| Deferred revenue, net of current portion | 33,653 | 28,691 |
| Other long-term liabilities | 775 | 574 |
| Total liabilities | 65,936 | 71,066 |
| Commitments and contingencies | ||
| Stockholders’ equity / Former Parent's deficit: | ||
| Preferred stock, $0.001 par value: 40,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.001 par value: 400,000 shares authorized; 17,106 shares issued and outstanding as of June 30, 2026, and no shares authorized, issued, or outstanding as of December 31, 2025 | 16 | — |
| Additional paid-in capital | 222,853 | — |
| Accumulated deficit | (8,058) | — |
| Accumulated other comprehensive loss, net | (235) | — |
| Net investment from Former Parent | — | (62,713) |
| Total stockholders’ equity / Former Parent’s deficit | 214,576 | (62,713) |
| Total liabilities and Stockholders’ equity / Former Parent’s deficit | 280,512 | 8,353 |
Condensed Statements of Cash Flows (Unaudited)
(in thousands)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | (36,819) | (20,328) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 494 | 132 |
| Stock-based compensation expense | 13,106 | 2,910 |
| Non-cash operating lease costs | 1,595 | 135 |
| Amortization of premiums and discounts on short-term investments, net | (250) | — |
| Changes in operating assets and liabilities: | ||
| Prepaid assets | (2,971) | (829) |
| Other current assets | (5,024) | (1,302) |
| Accounts payable | (885) | (221) |
| Accrued liabilities | 4,334 | 3,171 |
| Accrued compensation | 815 | 1,236 |
| Lease liabilities | (2,026) | (1,919) |
| Deferred revenues | (7,639) | (5,421) |
| Other long-term liabilities | 201 | (574) |
| Net cash used in operating activities | (35,069) | (23,010) |
| Cash flows from investing activities | ||
| Purchases of short-term investments | (191,551) | — |
| Purchases of property and equipment | (2,134) | (266) |
| Net cash used in investing activities | (193,685) | (266) |
| Cash flows from financing activities | ||
| Net transfers from Former Parent | 301,505 | 23,276 |
| Net cash provided by financing activities | 301,505 | 23,276 |
| Net increase in cash, cash equivalents, and restricted cash | 72,751 | — |
| Cash, cash equivalents and restricted cash, at beginning of period | — | — |
| Cash, cash equivalents and restricted cash, at end of period | 72,751 | — |
| Reconciliation of cash, cash equivalents and restricted cash, at end of period: | ||
| Cash and cash equivalents | 72,334 | — |
| Restricted cash included in current assets | 311 | — |
| Restricted cash included in non-current assets | 106 | — |
| Total cash, cash equivalents and restricted cash | 72,751 | — |
| Supplemental schedule of noncash investing and financing activities: | ||
| Costs incurred, but not paid, in connection with purchases of property and equipment included in accounts payable and accrued liabilities | — | 109 |
| Net assets distributed from Former Parent | — | 742 |
| Reclassification of deficit from Former Parent | 221,940 | — |
Amounts as printed on the EDGAR/iXBRL face — (in thousands except per share data); (in thousands, except par value); (in thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗